{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:38:13Z","timestamp":1787593093628,"version":"build-2736575974"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jjcc.2021.11.016","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T01:21:00Z","timestamp":1639704060000},"page":"691-697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Heart failure and its treatment from the perspective of sympathetic nerve activity"],"prefix":"10.1016","volume":"79","author":[{"given":"Shinya","family":"Minatoguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2021.11.016_bib0001","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/ejhf.319","article-title":"Heart failure as a general pandemic in Asia","volume":"17","author":"Shimokawa","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0002","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effect of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0003","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0004","first-page":"685","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction","volume":"372","author":"Yusuf","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0005","series-title":"Catecholamines and the heart: recent advances in experimental and clinical research","first-page":"236","article-title":"Catecholamines in patients with heart failure","author":"Maurer","year":"1981"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0006","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/0002-8703(95)90360-7","article-title":"Modulation of noradrenaline release through presynaptic alpha 2-adrenoceptors in congestive heart failure","volume":"130","author":"Minatoguchi","year":"1995","journal-title":"Am Heart J"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0007","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJM198409273111303","article-title":"Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure","volume":"311","author":"Cohn","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0008","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/01.CIR.94.4.690","article-title":"Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction","volume":"94","author":"Benedict","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0009","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijcard.2019.08.040","article-title":"Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction","volume":"296","author":"Vergaro","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0010","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00005344-199423030-00012","article-title":"Modulation of norepinephrine release in adriamycin-induced heart failure in rabbits: role of presynaptic a2-adrenoceptors and presynaptic angiotensin II receptors","volume":"23","author":"Minatoguchi","year":"1994","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0011","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1161\/01.CIR.73.4.615","article-title":"Norepinephrine spillover in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity","volume":"73","author":"Hasking","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0012","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1023\/A:1009846123893","article-title":"Chemoreflex in heart failure","volume":"5","author":"Shulz","year":"2000","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0013","doi-asserted-by":"crossref","first-page":"10G","DOI":"10.1016\/0002-9149(92)91250-8","article-title":"Baroreceptor reflex function in congestive heart failure","volume":"69","author":"Creager","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0014","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/01.CIR.73.5.913","article-title":"Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure","volume":"73","author":"Leimbach","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BFb0027645","article-title":"Pre-synaptic \u03b1-autoreceptors","volume":"107","author":"Starke","year":"1987","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0016","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1440-1681.1987.tb00996.x","article-title":"Modulation of noradrenaline release in vivo through prejunctional \u03b1-adrenoceptors","volume":"14","author":"Majewski","year":"1987","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0017","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1440-1681.1992.tb00493.x","article-title":"A comparison of guanfafine, bunazosin, atenolol and nadolol on blood pressure and plasma noradrenaline responses to cold pressor testing","volume":"19","author":"Koshiji","year":"1992","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0018","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/00005344-198409000-00023","article-title":"Modulation of noradrenaline release in the pithed rabbit: a role for angiotensin II","volume":"6","author":"Majewski","year":"1984","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0019","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/00005344-198910000-00014","article-title":"Angiotensin II and noradrenergic transmission in the pithed rat","volume":"14","author":"Majewski","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0020","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1440-1681.1992.tb00451.x","article-title":"Enalapril decreases plasma noradrenaline levels during the cold pressor test in human hypertensives","volume":"19","author":"Minatoguchi","year":"1992","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0021","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0167-5273(99)00095-9","article-title":"Effects of the angiotensin II antagonist losartan on endothelin-1 and norepinephrine plasma levels during cold pressor test in patients with chronic heart failure","volume":"70","author":"Rodriguez-Garcia","year":"1999","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0022","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/BF00586343","article-title":"The noradrenaline rate in the anaesthetized rabbit: facilitation by adrenaline","volume":"321","author":"Majewski","year":"1982","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0023","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00005344-198407000-00014","article-title":"Local modulation of noradrenaline release in vivo: presynaptic beta2-adrenoceptors adrenaline","volume":"6","author":"Schmidt","year":"1984","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0024","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1253\/jcj.57.426","article-title":"Modulation of noradrenaline release via activation of presynaptic beta-adrenoceptors in rabbits with adriamycin-induced cardiomyopathy","volume":"57","author":"Uno","year":"1993","journal-title":"Jpn Circ J"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0002-9343(86)90148-8","article-title":"Importance of receptor regulation in pathophysiology and therapy of congestive heart failure","volume":"80","author":"Ruffolo","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0026","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/med.2610060204","article-title":"Presynaptic beta-adrenoceptors","volume":"6","author":"Misu","year":"1986","journal-title":"Med Res Rev"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0027","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/ajh\/6.12.1016","article-title":"Role of presynaptic beta 2-adrenergic facilitation in the development and maintenance of DOCA-salt hypertension","volume":"6","author":"Moreau","year":"1993","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0028","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fneur.2014.00051","article-title":"\u03b21-blockers lower norepinephrine release by inhibiting presynaptic, facilitating \u03b21-adrenoceptors in normotensive and hypertensive rats","volume":"5","author":"Berg","year":"2014","journal-title":"Front Neurol"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0029","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0030","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0031","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1161\/01.CIR.96.4.1173","article-title":"Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure","volume":"96","author":"Grassi","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0032","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0002-8703(96)90186-6","article-title":"Angiotensin-converting enzyme inhibition, autonomic activity, and hemodynamics in patients with heart failure who perform isometric exercise","volume":"131","author":"Willenbrock","year":"1996","journal-title":"Am Heart J"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0033","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0034","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/01.CIR.0000036747.68104.AC","article-title":"Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT)","volume":"106","author":"Latini","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0035","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/ajh\/hpt188","article-title":"Telmisartan reduces mortality and left ventricular hypertrophy with sympathoinhibition in rats with hypertension and heart failure","volume":"27","author":"Kishi","year":"2014","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0036","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomized trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0037","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0038","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0039","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/hrt.74.4.431","article-title":"Reductions in muscle sympathetic nerve activity after long term metoprolol for dilated cardiomyopathy: preliminary observations","volume":"74","author":"Rahman","year":"1995","journal-title":"Br Heart J"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0040","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1253\/circj.CJ-16-0464","article-title":"Sympathetic nerve activity efferent drive and beta-blocker treatment- effect of interaction in systolic heart failure","volume":"80","author":"Joho","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0041","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0042","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0043","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/hr.2011.220","article-title":"Activation of mineralocorticoid receptors in the rostral ventrolateral medulla is involved in hypertensive mechanisms in stroke-prone spontaneously hypertensive rats","volume":"35","author":"Nakagaki","year":"2012","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0044","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/31255","article-title":"A family of hyperpolarization-activated mammalian cation channels","volume":"393","author":"Ludwig","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0045","first-page":"32","article-title":"From funny current to HCN channels: 20 years of excitation","volume":"17","author":"Accili","year":"2002","journal-title":"News Physiol Sci"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0046","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1161\/01.CIR.0000118464.48959.1C","article-title":"Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure","volume":"109","author":"Muller","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0047","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1159\/000447901","article-title":"The effects of ivabradine on cardiac function after myocardial infarction are weaker in diabetic rats","volume":"39","author":"Cao","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0048","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/1074248419829168","article-title":"Modulation of sympathetic activity and innervation with chronic ivabradine and \u03b2-blocker therapy: analysis of hypertensive rats with heart failure","volume":"24","author":"Kakehi","year":"2019","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0049","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0050","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0051","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jacc.2019.01.018","article-title":"B-type natriuretic peptide during treatment with sacubitril\/valsartan: The PARADIGM-HF Trial","volume":"73","author":"Myhre","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0052","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1161\/HYPERTENSIONAHA.114.05054","article-title":"Efficacy of B-type natriuretic peptide is coupled to phosphodiesterase 2A in cardiac sympathetic neurons","volume":"66","author":"Li","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0053","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0735-1097(01)01172-X","article-title":"Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects","volume":"37","author":"Brunner-La Rocca","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0054","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.jacc.2017.08.056","article-title":"Renal sympathetic denervation protects the failing heart via inhibition of neprilysin activity in the kidney","volume":"70","author":"Polhemus","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0055","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0056","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection","volume":"5","author":"Herat","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0057","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12933-019-0914-1","article-title":"Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction","volume":"18","author":"Zhang","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0058","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0059","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0060","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.2147\/JIR.S309427","article-title":"Empagliflozin alleviates atherosclerosis progression by inhibiting inflammation and sympathetic activity in a normoglycemic mouse model","volume":"14","author":"Liu","year":"2021","journal-title":"J Inflam Res"},{"key":"10.1016\/j.jjcc.2021.11.016_bib0061","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jash.2017.07.005","article-title":"The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus","volume":"11","author":"Jordan","year":"2017","journal-title":"J Am Soc Hypertens"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508721003373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508721003373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:06:00Z","timestamp":1760274360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508721003373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0914508721003373"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2021.11.016","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heart failure and its treatment from the perspective of sympathetic nerve activity","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2021.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}